乙型肝炎病毒(HBV)感染人体后,特异性细胞免疫是发病的关键环节,细胞免疫应答低下是HBV持续感染的关键因素。目前抗病毒治疗存在持续应答率低、疗程长、病毒变异等一系列问题,主要原因是抗病毒药物只能抑制HBV复制,都不能彻底清除共价闭合环状DNA(cccDNA),也与患者免疫缺陷不能得到充分恢复有一定的关系。因此,抗病毒治疗过程中,如何发挥现有药物各自优点,同时提高患者的特异性细胞免疫功能,加强免疫介导的病毒清除,从而达到彻底清除HBVcccDNA的目的,应成为关注的重点。 Hepatitis B virus (HBV) infection of the human body, the specific cellular immunity is the key link in the pathogenesis, cellular immune response is a key factor in persistent HBV infection. The current antiviral therapy has a series of problems such as low persistent response rate, long course of treatment and virus mutation. The main reason is that antiviral drugs can only inhibit HBV replication and can not completely eliminate the covalent closed circular DNA (cccDNA) Defects can not be fully restored to a certain extent. Therefore, in the course of antiviral therapy, how to give full play to the advantages of the existing drugs, and at the same time improve the patient’s specific cellular immune function and enhance immune-mediated virus clearance to achieve the purpose of completely eliminating HBVcccDNA should become the focus of attention.